The drug-development lifecycle generates scores of valuable imaging data pharmaceutical companies can leverage to accelerate R&D, make better-informed decisions about trial efficacy and develop AI models. But enabling data access, standardization and analysis in a timely manner is another story.
Learn how a top 10 biopharma company has centralized management of more than 200 million images, empowering teams to discover new biomarkers and develop and test AI models, including a new FDA-cleared model.
